Showing results (411-420 of 581) with videos related to
Sort By:
Pageof 59
Molecular Cancer Therapeutics|March 12, 2009
Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor modelAchuthamangalam B Madhankumar, Becky Slagle-Webb, Xinsheng Wang, et al.Journal of Pain and Symptom Management|August 30, 2008
Generating an African palliative care evidence base: the context, need, challenges, and strategiesRichard Harding, Richard A Powell, Julia Downing, et al.Microbial Genomics|April 13, 2023
Novel recombinant SARS-CoV-2 lineage detected through genomic surveillance in Wales, UKNicole Pacchiarini, Michelle Cronin, Clare Sawyer, et al.Biorxiv : the Preprint Server for Biology|August 6, 2025
Extracellular vesicles released from endothelial cells of the blood-brain barrier mediate brain Iron accumulation during LPS-induced brain InflammationKondaiah Palsa, Timothy B Helmuth, Aurosman Pappus Sahu, et al.BMC Genomics|July 26, 2012
A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencersMichael A Quail, Miriam Smith, Paul Coupland, et al.Arthritis and Rheumatism|July 15, 1998
Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthaseJ P Pelletier, D Jovanovic, J C Fernandes, et al.Plos One|April 20, 2026
Systemic iron availability differentially shapes tumor and brain iron handling in a sex-dependent manner in glioblastomaEmily Tufano, Kondaiah Palsa, Rebecka O Serpa, et al.Nucleic Acids Research|November 22, 2014
Rapid phylogenetic analysis of large samples of recombinant bacterial whole genome sequences using GubbinsNicholas J Croucher, Andrew J Page, Thomas R Connor, et al.Bioorganic & Medicinal Chemistry Letters|October 24, 2002
3-Hydroxy-4-methyl-5-pentyl-2-iminopyrrolidine: a potent and highly selective inducible nitric oxide synthase inhibitorSofya Tsymbalov, Timothy J Hagen, William M Moore, et al.Journal of Virology|August 17, 2001
Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease statusJ F Kreisberg, D Kwa, B Schramm, et al.Pageof 59